Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4327-4342

  Kang, Hee E ^a   Jung, Hye Y ^a   Cho, Yu K ^a   Kim, So H ^b   Sohn, Se I ^c   Baek, Seung R ^c   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Gangneung Wonju National University   (South Korea)

^c Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

Animal scale up; CL (CL f u) and Vss (Vss fu); Complex Dedrick plot; Liquiritigenin, M1 and M2; Mice, rats, rabbits, and dogs; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; LIQUIRITIGENIN; LIQUIRITIGENIN 4' O GLUCURONIDE; LIQUIRITIGENIN 7 O GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EXPERIMENTAL DOG; EXPERIMENTAL RABBIT; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; RAT; SCALE UP; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70349634349     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21702     Document Type: Article

References (29)

1. Shimamura H, Suzuki H, Hanano M, Suzuki A, Tagaya O, Horie T, Sugiyama Y. 1994. Multiple systems for the biliary excretion of organic anions in rats: Liquiritigenin conjugates as model compounds. J Pharmacol Exp Ther 271:370-378. (Pubitemid 24333151)
2. Kim SC, Byun SH, Yang CH, Kim CY, Kim JW, Kim SG. 2004. Cytoprotective effects of Glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage). Toxicology 197:239-251.
3. Kim YW, Ki SH, Lee JR, Lee SJ, Kim CW, Kim SC, Kim SG. 2006. Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine. Chem Biol Interact 161:125-138.
4. Shimamura H, Suzuki H, Hanano M, Suzuki A, Sugiyama Y. 1993. Identification of tissues responsible for the conjugative metabolism of liquiritigenin in rats: An analysis based on metabolite kinetics. Biol Pharm Bull 16:899-907. (Pubitemid 23329802)
5. Shimamura H, Nakai S, Yamamoto K, Hitomi N, Yumioka E. 1990. Biliary and urinary metabolites of liquiritigenin in rats. Jpn J Pharmacogn 44:265-268. (Pubitemid 20138394)
6. Kang HE, Choi KY, Lee MG. Determination of an agent for the inflammatory liver disease, liquiritigenin, in rat plasma, urine, and various tissue homogenates by high-performance liquid chromatography. In: Proceedings of the Spring International Convention of the Pharmaceutical Society of Korea, International Convention Center, Jeju, South Korea, April 30-May 3, 2008; Abstract p. 342.
7. Kang HE, Yang SH, Lee MG. Dose-independent pharmacokinetics of liquiritigenin after intravenous and oral administration to rats: Contribution of hepatic and gastric first-pass effect to low bioavailability in rats. In: Proceedings of the Spring International Convention of the Pharmaceutical Society of Korea, International Convention Center, Jeju, South Korea, April 30-May 3, 2008; Abstract p. 344.
8. Adolph EF. 1949. Quantitative relations in the physiological constitutions of mammals. Science 109:579-585.
9. Shim HJ, Kim YC, Lee JH, Kwon JW, Kim WB, Kim YG, Kim SH, Lee MG. 2005. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 26:269-277. (Pubitemid 41601260)
10. Shibayama T, Matsushita Y, Kurihara A, Hirota T, Ikeda T. 2007. Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data. Xenobiotica 37:91-102. (Pubitemid 46009559)
11. Boxenbaum M. 1984. Interspecies pharmacokinetic scaling and the evolutionary comparative paradigm. Drug Metab Rev 15:1071-1121.
12. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
13. Chang HW, Lee MG, Lee H, Park MK, Kim C-K. 1992. Effects of leucovorin on the pharmacokinetics of methotrexate in rabbits. Int J Pharm 79:71-75.
14. Chiou WL, Riegelman S, Amberg JR. 1969. Complication in using rabbits for the study of oral drug absorption. Chem Pharm Bull 17:2170-2173.
15. Lui CY, Lee MG, Chiou WL. 1985. Clearance studies of methotrexate in dogs after multiple-rate infusion. Cancer Res 45:1545-1548. (Pubitemid 15079101)
16. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. 2000. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291. (Pubitemid 32747118)
17. Boudinot FD, Jusko WJ. 1984. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774-780. (Pubitemid 14122792)
18. Øie S, Guentert TW. 1982. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 71:127-128.
19. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd edition. New York: Marcel-Dekker, Inc.
20. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
21. Boxenbaum H, Ronfeld R. 1983. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R678-R774.
22. Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishmura T, Inaba M, Kobayashi T. 1990. Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. Cancer Chemother Pharmacol 27:20-26.
23. Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. 2003. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326-333. (Pubitemid 36249688)
24. Davis B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
25. Dedrick RL. 1973. Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
26. Paxton JW, Kim SN, Whitfield LR. 1990. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res 50:2692-2697.
27. Dedrick RL, Bischoff KB, Zaharko DS. 1970. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95-101.
28. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. 1996. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641. (Pubitemid 27167181)
29. Mordenti J. 1991. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040. (Pubitemid 17216546)